# Oncolytics Biotech Inc. (ONCY) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ONCY
## Company Profile
- Ticker: ONCY
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada and listed in the U
- Tags: Oncolytic Virus, Oncology
## Stock Data
- Close: 0.5444 USD
- Market cap: 110712832.5492 USD
- Last updated: 2026-10-08
## Business Overview
Oncolytics Biotech is an oncology company focused on oncolytic virus therapy and immune activation in cancer. Its story is built around using a viral platform to trigger stronger anti-tumor responses in difficult solid tumors.
## Why The Stock Is Moving

As of Oct 8, 2026, ONCY closed down 8.63% at $0.5444. No new same-company headline was identified in the current news window.

## Geographic Base

Oncolytics is headquartered in Canada and listed in the U.S. market. It sits in small-cap oncology biotechnology.

## Business Model

The company depends on clinical validation, translational confidence, and capital support while it develops a narrow cancer platform. Investors usually watch efficacy, safety, and partnership interest.

## Landscape Position

Oncolytics occupies a specialized oncolytic-virus niche within biotech. The stock is catalyst-sensitive because the market still needs proof that the platform can create durable clinical value.

## Future Catalysts

- Oncolytics’ catalysts are pelareorep and the oncology-combination program, where the next clinical update can materially move the stock. The company remains highly dependent on human data.

## Recent News
- 2026-09-29 13:30 EST — [Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-publication-demonstrating-pelareorep-creates-immune-77c2c304) — Source: Oncolytics Biotech Inc.
- 2026-09-28 13:30 EST — [Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-reports-accelerating-enrollment-in-randomized-reo-033-ras-mut-c5320cbe) — Source: Oncolytics Biotech Inc.
- 2026-09-10 12:15 EST — [Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-announces-positive-preclinical-results-combining-pelareorep-w-cffe8027) — Source: Oncolytics Biotech Inc.
- 2026-08-18 13:00 EST — [Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-aligns-with-fda-on-registrational-path-for-second-line-ras-mu-9d983733) — Source: Oncolytics Biotech Inc.
- 2026-07-20 13:00 EST — [Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer](https://biopharmsignal.com/news/ONCY/oncolytics-biotech-receives-fast-track-designation-for-pelareorep-in-second-line-a2a9c705) — Source: Oncolytics Biotech Inc.